Funded Biotechnology Startups in Singapore
The 27 Singapore-based biotechnology companies shown here span rounds from a $100K pre-seed (BioDefense, May 2024) to a $140M Series B (RVAC Medicines, Apr…
The 27 Singapore-based biotechnology companies shown here span rounds from a $100K pre-seed (BioDefense, May 2024) to a $140M Series B (RVAC Medicines, April 2022), with Nuevocor's $45M Series B in May 2025 marking the most recent disclosed close. All entries are headquartered in Singapore's Central Region, reflecting the concentration of life sciences activity around Biopolis and the broader one-north cluster. Three sub-sectors dominate: therapeutics and drug development (RVAC Medicines, SCG Cell Therapy, Tetris Therapeutics, Albatroz Therapeutics, Neuroglee Therapeutics), molecular diagnostics and genomics (Mirxes, Aevice Health, ImmunoScape, Nalagenetics), and food biotechnology (Another Food, Meatiply, Alchemy Foodtech).
Seed is the most frequently labeled stage, with seven companies at that level — including DotBio ($6M, August 2023) and Auristone ($4M, April 2024). Eight entries carry a "Series Unknown" classification and several list undisclosed amounts, so disclosed totals represent only a portion of actual capital deployed into this cohort.
Most recent rounds
27 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Singapore biotech companies shown here?
RVAC Medicines leads with a $140M Series B closed in April 2022. The next largest are Nuevocor at $45M (Series B, May 2025), Mirxes at $40M (Series Unknown, January 2025), and Apeiron Bioenergy at $37M (Series Unknown, June 2023). Below those, Automera raised $16M at Series A in September 2023 and Tetris Therapeutics raised $15M at Seed in May 2022.
Which biotech sub-sectors are most represented in Singapore's recent funding activity?
Therapeutics — including cell therapy, oncology, and neurology — accounts for the broadest cluster, with RVAC Medicines, SCG Cell Therapy, Albatroz Therapeutics, Tetris Therapeutics, Automera, and Neuroglee Therapeutics all appearing. Molecular diagnostics and genomics is a second clear grouping (Mirxes, Aevice Health, ImmunoScape, Nalagenetics), and food biotechnology forms a third (Another Food, Meatiply, Alchemy Foodtech).
How much funding activity has occurred in 2024 and 2025?
Eight of the 27 rounds shown closed in 2024 or 2025. The 2025 entries are Nuevocor ($45M Series B, May), Mirxes ($40M, January), and Aevice Health (undisclosed, January). The 2024 entries are ASLAN Pharmaceuticals ($5M, March), Auristone ($4M Seed, April), BioDefense ($100K Pre-Seed, May), Another Food (undisclosed, June), and ImmunoScape ($250K, September).
What is the typical deal size for seed-stage Singapore biotech companies in this data?
Six of the seven seed rounds show disclosed amounts: $3M (Albatroz Therapeutics), $4M each (Auristone, Meatiply), $5M (Allozymes), $6M (DotBio), and $15M (Tetris Therapeutics). Five of those six fall in the $3M–$6M range; Tetris Therapeutics at $15M is the clear outlier.
How many of the rounds have unspecified stages or undisclosed amounts?
Eight companies carry a 'Series Unknown' stage label, and two more — ASLAN Pharmaceuticals and TurtleTree Labs — have no round type listed at all. On amounts, at least four rounds are undisclosed: Aevice Health, Another Food, Carcell Biopharma, and Allium Bio. This limits direct comparisons across a meaningful portion of the dataset.
Are there late-stage (Series B or higher) Singapore biotech companies in this dataset?
Four companies show Series B or Series C rounds. RVAC Medicines raised $140M at Series B (April 2022) and Nuevocor raised $45M at Series B (May 2025). SCG Cell Therapy closed a Series C at $8M (April 2023) and Curiox Biosystems closed a Series C at $15M (March 2022).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.